Provided by Tiger Trade Technology Pte. Ltd.

Aura Biosciences, Inc.

7.50
+0.07000.94%
Post-market: 7.500.00000.00%16:15 EDT
Volume:495.49K
Turnover:3.70M
Market Cap:775.40M
PE:-4.23
High:7.67
Open:7.46
Low:7.00
Close:7.43
52wk High:9.54
52wk Low:4.73
Shares:103.39M
Float Shares:79.92M
Volume Ratio:0.96
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7726
EPS(LYR):-1.7599
ROE:-53.49%
ROA:-31.24%
PB:2.46
PE(LYR):-4.26

Loading ...

Aura Biosciences to Participate in Upcoming Investor Conference

GlobeNewswire
·
1 hour ago

Aura Biosciences Grants New Executives Stock Options Priced at $7.43, Plus RSUs

Reuters
·
Yesterday

Aura Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Yesterday

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Yesterday

Aura Biosciences Extends Bel-sar Data With Long-Term Follow-Up Study

TIPRANKS
·
Aug 20

Aura Biosciences files $500M mixed securities shelf

TIPRANKS
·
Aug 17

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP)

TIPRANKS
·
Aug 13

Aura Biosciences COO Susan Abu-Absi Files Initial Beneficial Ownership Statement

Reuters
·
Aug 13

Aura Biosciences - May Offer Securities up to $500 Million Aggregate

Reuters
·
Aug 12

Aura Biosciences - May Sell up to $200 Mln Common Stock Under Sales Agreement with Jefferies - SEC Filing

THOMSON REUTERS
·
Aug 12

Aura Biosciences is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 12

Aura Biosciences, Inc. : H.c. Wainwright Cuts Target Price to $18 from $24

THOMSON REUTERS
·
Aug 11

Aura Biosciences Releases Corporate Deck Outlining Bel-Sar Strategy in Ocular Oncology

Reuters
·
Aug 11

Aura Biosciences Q2 Loss Widens

MT Newswires Live
·
Aug 11

Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) Estimate

Benzinga Earnings
·
Aug 11

Earnings Flash (AURA) Aura Biosciences Posts Q2 Net Loss $0.48 a Share, vs. FactSet Est of $0.37 Loss

MT Newswires Live
·
Aug 11

Aura Biosciences, - Phase 3 Compass Trial Fully Enrolled with 108 Patients; Topline Data Expected in 2H 2027

THOMSON REUTERS
·
Aug 11

Aura Biosciences, - Reduces Workforce by About 20% to Focus on Ocular Oncology

THOMSON REUTERS
·
Aug 11

Aura Biosciences, - Organizational Restructuring and Capital Allocation Extend Cash Runway into 1H 2029

THOMSON REUTERS
·
Aug 11

Press Release: Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Dow Jones
·
Aug 11